What type of study is this?

This is a Cohort Study study (also classified as: Quantitative Study).

September 20, 2025Annals of HematologyOpen Access

Real-world study on patient characteristics, treatment patterns and outcomes for treated patients with chronic lymphocytic leukemia during 2013–2022 in Finland

View Full Paper

Ask AI

Bookmark

Authors

Real-world study reports survival rates and treatment approaches for chronic lymphocytic leukemia patients, highlighting trends in genetic testing.

The 3-year survival rate of chronic lymphocytic leukemia patients increased from 69% to 73% from 2013–2022.
Targeted therapies became the most common first-line treatment choice from 2018–2022, shifting from chemotherapy.
A notable 64% of patients had unknown del(17)p/TP53 status, and 79% lacked information on IGHV mutational status.
While total healthcare resource utilization remained stable, changes in outpatient contact types were observed over time.

Ranti et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 20, 2025Annals of HematologyOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Real-world study reports survival rates and treatment approaches for chronic lymphocytic leukemia patients, highlighting trends in genetic testing.

The 3-year survival rate of chronic lymphocytic leukemia patients increased from 69% to 73% from 2013–2022.
Targeted therapies became the most common first-line treatment choice from 2018–2022, shifting from chemotherapy.
A notable 64% of patients had unknown del(17)p/TP53 status, and 79% lacked information on IGHV mutational status.
While total healthcare resource utilization remained stable, changes in outpatient contact types were observed over time.

Ranti et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark